vs
Anika Therapeutics, Inc.（ANIK）与MERIT MEDICAL SYSTEMS INC（MMSI）财务数据对比。点击上方公司名可切换其他公司
MERIT MEDICAL SYSTEMS INC的季度营收约是Anika Therapeutics, Inc.的12.9倍（$393.9M vs $30.6M）。MERIT MEDICAL SYSTEMS INC净利率更高（9.6% vs 1.0%，领先8.7%）。MERIT MEDICAL SYSTEMS INC同比增速更快（10.9% vs 0.0%）。MERIT MEDICAL SYSTEMS INC自由现金流更多（$74.0M vs $4.0M）。过去两年MERIT MEDICAL SYSTEMS INC的营收复合增速更高（10.3% vs 2.7%）
梅里特医疗系统公司是一家全球性医疗设备企业，设计、生产和销售适用于心脏病学、放射学、肿瘤学、内窥镜及重症监护领域的介入和诊断产品，为全球医院及医疗机构提供微创医疗解决方案，助力提升患者疗效和临床操作效率。
ANIK vs MMSI — 直观对比
营收规模更大
MMSI
是对方的12.9倍
$30.6M
营收增速更快
MMSI
高出10.9%
0.0%
净利率更高
MMSI
高出8.7%
1.0%
自由现金流更多
MMSI
多$70.1M
$4.0M
两年增速更快
MMSI
近两年复合增速
2.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $30.6M | $393.9M |
| 净利润 | $292.0K | $38.0M |
| 毛利率 | 62.6% | 49.6% |
| 营业利润率 | 2.1% | 13.8% |
| 净利率 | 1.0% | 9.6% |
| 营收同比 | 0.0% | 10.9% |
| 净利润同比 | 101.3% | 36.0% |
| 每股收益（稀释后） | $0.02 | $0.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIKMMSI
| Q4 25 | $30.6M | $393.9M | ||
| Q3 25 | $27.8M | $384.2M | ||
| Q2 25 | $28.2M | $382.5M | ||
| Q1 25 | $26.2M | $355.4M | ||
| Q4 24 | $30.6M | $355.2M | ||
| Q3 24 | $29.6M | $339.8M | ||
| Q2 24 | $30.7M | $338.0M | ||
| Q1 24 | $29.0M | $323.5M |
净利润ANIKMMSI
| Q4 25 | $292.0K | $38.0M | ||
| Q3 25 | $-2.3M | $27.8M | ||
| Q2 25 | $-4.0M | $32.6M | ||
| Q1 25 | $-4.9M | $30.1M | ||
| Q4 24 | $-21.9M | $27.9M | ||
| Q3 24 | $-29.9M | $28.4M | ||
| Q2 24 | $-88.0K | $35.7M | ||
| Q1 24 | $-4.5M | $28.2M |
毛利率ANIKMMSI
| Q4 25 | 62.6% | 49.6% | ||
| Q3 25 | 56.0% | 48.5% | ||
| Q2 25 | 50.9% | 48.2% | ||
| Q1 25 | 56.1% | 48.4% | ||
| Q4 24 | 56.0% | 48.7% | ||
| Q3 24 | 65.7% | 46.4% | ||
| Q2 24 | 66.7% | 47.7% | ||
| Q1 24 | 65.4% | 46.9% |
营业利润率ANIKMMSI
| Q4 25 | 2.1% | 13.8% | ||
| Q3 25 | -11.6% | 11.1% | ||
| Q2 25 | -14.8% | 12.3% | ||
| Q1 25 | -16.4% | 11.5% | ||
| Q4 24 | -2.3% | 10.3% | ||
| Q3 24 | -0.3% | 11.0% | ||
| Q2 24 | -5.9% | 13.6% | ||
| Q1 24 | -8.6% | 11.1% |
净利率ANIKMMSI
| Q4 25 | 1.0% | 9.6% | ||
| Q3 25 | -8.4% | 7.2% | ||
| Q2 25 | -14.1% | 8.5% | ||
| Q1 25 | -18.6% | 8.5% | ||
| Q4 24 | -71.4% | 7.9% | ||
| Q3 24 | -101.2% | 8.4% | ||
| Q2 24 | -0.3% | 10.6% | ||
| Q1 24 | -15.6% | 8.7% |
每股收益（稀释后）ANIKMMSI
| Q4 25 | $0.02 | $0.64 | ||
| Q3 25 | $-0.16 | $0.46 | ||
| Q2 25 | $-0.28 | $0.54 | ||
| Q1 25 | $-0.34 | $0.49 | ||
| Q4 24 | $-1.49 | $0.46 | ||
| Q3 24 | $-2.03 | $0.48 | ||
| Q2 24 | $0.00 | $0.61 | ||
| Q1 24 | $-0.31 | $0.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $81.2M | $446.4M |
| 总债务越低越好 | — | $734.0M |
| 股东权益账面价值 | $143.5M | $1.6B |
| 总资产 | $190.3M | $2.7B |
| 负债/权益比越低杠杆越低 | — | 0.46× |
8季度趋势，按日历期对齐
现金及短期投资ANIKMMSI
| Q4 25 | $81.2M | $446.4M | ||
| Q3 25 | $80.2M | $392.5M | ||
| Q2 25 | $77.1M | $341.8M | ||
| Q1 25 | $75.4M | $395.5M | ||
| Q4 24 | $79.2M | $376.7M | ||
| Q3 24 | $90.7M | $523.1M | ||
| Q2 24 | $96.6M | $636.7M | ||
| Q1 24 | $100.7M | $581.9M |
总债务ANIKMMSI
| Q4 25 | — | $734.0M | ||
| Q3 25 | — | $732.9M | ||
| Q2 25 | — | $731.8M | ||
| Q1 25 | — | $730.7M | ||
| Q4 24 | — | $729.6M | ||
| Q3 24 | — | $750.5M | ||
| Q2 24 | — | $801.3M | ||
| Q1 24 | — | $800.1M |
股东权益ANIKMMSI
| Q4 25 | $143.5M | $1.6B | ||
| Q3 25 | $146.8M | $1.5B | ||
| Q2 25 | $147.7M | $1.5B | ||
| Q1 25 | $148.4M | $1.4B | ||
| Q4 24 | $154.0M | $1.4B | ||
| Q3 24 | $179.9M | $1.3B | ||
| Q2 24 | $210.3M | $1.3B | ||
| Q1 24 | $208.5M | $1.2B |
总资产ANIKMMSI
| Q4 25 | $190.3M | $2.7B | ||
| Q3 25 | $189.4M | $2.6B | ||
| Q2 25 | $187.7M | $2.6B | ||
| Q1 25 | $190.6M | $2.5B | ||
| Q4 24 | $202.7M | $2.4B | ||
| Q3 24 | $231.4M | $2.4B | ||
| Q2 24 | $262.7M | $2.4B | ||
| Q1 24 | $263.7M | $2.3B |
负债/权益比ANIKMMSI
| Q4 25 | — | 0.46× | ||
| Q3 25 | — | 0.48× | ||
| Q2 25 | — | 0.49× | ||
| Q1 25 | — | 0.51× | ||
| Q4 24 | — | 0.53× | ||
| Q3 24 | — | 0.57× | ||
| Q2 24 | — | 0.62× | ||
| Q1 24 | — | 0.65× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.6M | $98.5M |
| 自由现金流经营现金流 - 资本支出 | $4.0M | $74.0M |
| 自由现金流率自由现金流/营收 | 13.0% | 18.8% |
| 资本支出强度资本支出/营收 | 2.1% | 6.2% |
| 现金转化率经营现金流/净利润 | 15.88× | 2.59× |
| 过去12个月自由现金流最近4个季度 | $4.4M | $215.7M |
8季度趋势，按日历期对齐
经营现金流ANIKMMSI
| Q4 25 | $4.6M | $98.5M | ||
| Q3 25 | $6.9M | $75.0M | ||
| Q2 25 | $-189.0K | $83.3M | ||
| Q1 25 | $-130.0K | $40.6M | ||
| Q4 24 | $1.6M | $68.7M | ||
| Q3 24 | $5.0M | $47.3M | ||
| Q2 24 | $-1.1M | $68.5M | ||
| Q1 24 | $-126.0K | $36.2M |
自由现金流ANIKMMSI
| Q4 25 | $4.0M | $74.0M | ||
| Q3 25 | $5.0M | $52.5M | ||
| Q2 25 | $-1.7M | $69.6M | ||
| Q1 25 | $-3.0M | $19.5M | ||
| Q4 24 | $275.0K | $65.3M | ||
| Q3 24 | $3.8M | $38.0M | ||
| Q2 24 | $-4.5M | $57.9M | ||
| Q1 24 | $-1.9M | $24.5M |
自由现金流率ANIKMMSI
| Q4 25 | 13.0% | 18.8% | ||
| Q3 25 | 17.9% | 13.7% | ||
| Q2 25 | -5.9% | 18.2% | ||
| Q1 25 | -11.3% | 5.5% | ||
| Q4 24 | 0.9% | 18.4% | ||
| Q3 24 | 12.9% | 11.2% | ||
| Q2 24 | -14.6% | 17.1% | ||
| Q1 24 | -6.7% | 7.6% |
资本支出强度ANIKMMSI
| Q4 25 | 2.1% | 6.2% | ||
| Q3 25 | 6.8% | 5.8% | ||
| Q2 25 | 5.2% | 3.6% | ||
| Q1 25 | 10.8% | 5.9% | ||
| Q4 24 | 4.3% | 1.0% | ||
| Q3 24 | 4.1% | 2.8% | ||
| Q2 24 | 11.1% | 3.1% | ||
| Q1 24 | 6.2% | 3.6% |
现金转化率ANIKMMSI
| Q4 25 | 15.88× | 2.59× | ||
| Q3 25 | — | 2.70× | ||
| Q2 25 | — | 2.56× | ||
| Q1 25 | — | 1.35× | ||
| Q4 24 | — | 2.46× | ||
| Q3 24 | — | 1.66× | ||
| Q2 24 | — | 1.92× | ||
| Q1 24 | — | 1.28× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIK
| OEM Channel | $17.3M | 57% |
| Commercial Channel | $13.3M | 43% |
MMSI
| Other | $154.6M | 39% |
| Peripheral Intervention | $93.2M | 24% |
| Cardiac Intervention | $50.2M | 13% |
| OEM | $42.6M | 11% |
| Custom Procedural Solutions | $33.1M | 8% |
| Endoscopy Segment | $20.1M | 5% |
